Alseres Pharmaceuticals, Inc.
ALSE · OTC
12/31/2013 | 12/31/2012 | 12/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Market Cap | $720 | $490 | $1,422 | $3,202 |
| - Cash | $114 | $17 | $136 | $99 |
| + Debt | $7,820 | $6,410 | $27,728 | $33,756 |
| Enterprise Value | $8,426 | $6,884 | $29,014 | $36,860 |
| Revenue | $474 | $531 | $0 | $0 |
| % Growth | -10.7% | – | – | – |
| Gross Profit | $450 | $531 | $0 | $0 |
| % Margin | 95% | 100% | – | – |
| EBITDA | -$486 | -$1,210 | -$1,003 | -$9,343 |
| % Margin | -102.6% | -228% | – | – |
| Net Income | -$942 | -$1,645 | -$2,882 | $512 |
| % Margin | -198.8% | -310% | – | – |
| EPS Diluted | -153.67 | -268.56 | -486.45 | 81.12 |
| % Growth | 42.8% | 44.8% | -699.7% | – |
| Operating Cash Flow | -$1,687 | -$952 | -$2,485 | -$2,951 |
| Capital Expenditures | $0 | $0 | -$2 | $0 |
| Free Cash Flow | -$1,687 | -$952 | -$2,487 | -$2,951 |